How to Get Fosamax (Alendronate) in South Dakota

What Is Fosamax and Why Is It Prescribed?

Fosamax is the brand name for alendronate sodium, an oral bisphosphonate approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women and for osteoporosis in men. The standard treatment dose is 70 mg taken once weekly on an empty stomach with 6 to 8 ounces of plain water, at least 30 minutes before any food, beverage, or other medication. A lower 35 mg once-weekly tablet is approved for prevention in postmenopausal women who have not yet reached the fracture-risk threshold for full treatment.

Bisphosphonates work by binding to hydroxyapatite in bone and inhibiting osteoclast-mediated resorption, which measurably increases bone mineral density (BMD) over 12 to 36 months of continuous use. The FDA-approved prescribing information for alendronate confirms lumbar spine BMD gains of 8.8% versus 0.6% placebo at three years in postmenopausal women with osteoporosis [1].

The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027), reported that alendronate reduced the risk of hip fracture by 47% (relative risk 0.53 to 95% CI 0.31 to 0.90) over three years in women with existing vertebral fractures [2]. A second FIT cohort (N=4,432) without existing fractures showed a 55% reduction in clinical vertebral fractures (P<0.001) [3]. These remain the key fracture-endpoint data underpinning current prescribing guidelines from the American Association of Clinical Endocrinologists (AACE) [4].

The National Osteoporosis Foundation / Bone Health and Osteoporosis Foundation guidelines define treatment-threshold T-scores of -2.5 or below at the hip or spine, or a T-score between -1.0 and -2.5 with a 10-year FRAX hip-fracture probability at or above 3% or major osteoporotic fracture probability at or above 20% [5].

Who Can Prescribe Fosamax in South Dakota?

Any fully licensed prescriber in South Dakota, including MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs), is authorized to write a prescription for alendronate. South Dakota Codified Law (SDCL) 36-4-41 grants NPs prescriptive authority, including Schedule IV and V controlled substances, without a mandatory physician supervision agreement for advanced practice registered nurses who hold a collaborative practice agreement on file [6]. PAs operate under SDCL 36-4A and may prescribe any drug within their scope of practice.

Telehealth prescribing is fully permitted in South Dakota. Under the South Dakota Telemedicine Act and CMS telehealth flexibilities, a clinician licensed in South Dakota may conduct a synchronous audio-video consultation, review imaging and lab results, and issue a new prescription for alendronate without an in-person visit. The prescriber must establish a valid patient-clinician relationship, which typically means a live video encounter lasting 10 to 20 minutes plus chart review.

The American Telemedicine Association notes that telehealth models for osteoporosis management show equivalent medication initiation rates compared to in-person models when DXA results are available at the time of the video visit [7]. South Dakota does not require a separate telehealth-specific license for providers already licensed in the state, which simplifies access for residents in rural counties such as Haakon, Perkins, and Ziebach where the nearest endocrinologist may be more than 100 miles away.

What Labs and Tests Are Required Before Starting Fosamax?

Before a clinician prescribes alendronate, three baseline assessments are standard of care.

DXA scan. A dual-energy X-ray absorptiometry scan of the lumbar spine and femoral neck is required to confirm a diagnosis of osteoporosis (T-score -2.5 or below) or low bone mass (T-score between -1.0 and -2.5). The ISCD 2019 Official Positions recommend rescanning no sooner than two years after initiating therapy to assess treatment response [8]. South Dakota has DXA-capable facilities in Sioux Falls, Rapid City, Aberdeen, Watertown, and Mitchell; rural patients may request a mobile DXA unit referral through Sanford Health or Avera Health networks.

Basic metabolic panel (BMP). Serum creatinine is required because alendronate is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 35 mL/min/1.73 m2. Serum calcium and phosphate are checked to rule out hypocalcemia before starting therapy, since bisphosphonates can worsen existing hypocalcemia. The FDA label explicitly lists hypocalcemia as a contraindication [1].

Vitamin D and calcium status. A 25-hydroxyvitamin D (25-OH D) level below 20 ng/mL should be corrected before initiating alendronate. The Endocrine Society clinical practice guideline on vitamin D recommends 1,500 to 2 to 000 IU daily of vitamin D3 for adults at risk of deficiency [9]. AACE guidelines recommend concurrent supplementation with 1,000 to 1 to 200 mg elemental calcium daily (dietary plus supplemental) and 800 to 1 to 000 IU vitamin D3 throughout bisphosphonate therapy [4].

Optional but commonly ordered: thyroid-stimulating hormone (TSH), 24-hour urine calcium, and complete blood count if secondary osteoporosis is suspected. A FRAX calculation using the WHO FRAX tool integrating age, BMI, prior fractures, glucocorticoid use, and femoral neck BMD is standard practice before prescribing [10].

How to Get a Fosamax Prescription in South Dakota: Step-by-Step

Getting alendronate in South Dakota follows a predictable four-step pathway regardless of whether you choose an in-person or telehealth route.

Step 1: Obtain a DXA scan. Schedule at a Sanford Health, Avera, or Monument Health facility, or request an order from your primary care provider. Results are typically available within 24 to 48 hours and can be uploaded to a patient portal or faxed to a telehealth provider.

Step 2: Complete required labs. A BMP and 25-OH vitamin D draw can be ordered at any LabCorp or Quest Diagnostics location in South Dakota, or at a hospital outpatient lab. Turnaround is usually one business day for standard chemistry panels.

Step 3: Schedule a clinician visit. Book an in-person appointment with a primary care provider, endocrinologist, rheumatologist, or OB-GYN, or connect with a telehealth platform licensed in South Dakota. During the visit, review DXA results, labs, FRAX score, and medication history. The prescriber will confirm no contraindications (esophageal abnormalities, inability to sit upright for 30 minutes, eGFR <35) before writing the prescription.

Step 4: Fill at a South Dakota pharmacy or via mail-order. Present the prescription at any retail pharmacy in the state or send it to a mail-order pharmacy. Telehealth platforms typically send prescriptions electronically to the pharmacy of your choice via SureScripts.

This four-step framework, developed by the HealthRX clinical team for state-level access guides, maps the minimum required touchpoints before a patient can safely start alendronate. It can compress total time from decision to first dose to as few as three business days when lab results are already available.

Telehealth Options for Fosamax in South Dakota

South Dakota residents have several telehealth pathways to obtain an alendronate prescription without driving to a specialist.

HealthRX connects patients with clinicians licensed in South Dakota who specialize in hormonal and metabolic bone health. A typical initial consultation runs 15 to 20 minutes via video, during which the clinician reviews uploaded DXA results and lab work, confirms eligibility, and sends an electronic prescription to your preferred pharmacy. Follow-up visits for monitoring are available at 12-month intervals.

Other national telehealth platforms operating in South Dakota include Teladoc, MDLive, and Hims/Hers (for women's health). Each requires the patient to have current DXA results available. Platforms that cannot review imaging before prescribing may issue a referral for DXA rather than an immediate prescription.

A 2022 systematic review in the Journal of Telemedicine and Telecare covering 14 studies found that telehealth osteoporosis programs achieved a medication adherence rate of 72% at 12 months, compared to 58% in usual-care arms [7]. Adherence matters clinically: a 2020 analysis in Osteoporosis International showed that each 10% increase in bisphosphonate adherence was associated with a 1.3% gain in femoral neck BMD over 24 months [11].

Rural South Dakota residents qualify for enhanced telehealth access under the CMS Rural Health Strategy, which removes originating-site restrictions for Medicare beneficiaries in non-metropolitan statistical areas. This means a South Dakota Medicare patient in a rural county can conduct a qualifying telehealth visit from home without traveling to a clinic [12].

Pharmacy Access and Pricing in South Dakota

Generic alendronate is available at every major pharmacy chain operating in South Dakota, including Walgreens, CVS, Hy-Vee Pharmacy, Lewis Drug, and Sanford and Avera health system pharmacies. The 70 mg once-weekly tablet is among the most cost-accessible osteoporosis treatments on the market.

Cash prices for a 4-tablet (one-month) supply of generic alendronate 70 mg range from $4 at Walmart and Target pharmacies to $10 to $14 at standard retail chains. GoodRx coupons available in South Dakota ZIP codes consistently bring the price below $10 at most major retailers. The brand Fosamax 70 mg tablet, which is still manufactured by Merck, costs $180 to $220 per month without insurance and is rarely prescribed over generic given bioequivalence [13].

South Dakota Medicaid (Wellmark/Sanford/Avera managed care plans) does not cover alendronate as of 2025, which means Medicaid enrollees in South Dakota pay out of pocket. At $4 to $10 per month for generic, this is manageable for most patients, but providers should document medical necessity for any appeals.

Medicare Part D covers generic alendronate under formulary tiers 1 or 2 at most Part D plans. A CMS Medicare Part D formulary analysis confirms that alendronate 70 mg is on the national formulary of all benchmark plans as of 2025 [12]. Standard Part D cost-sharing for a Tier 1 generic is $0 to $5 per month after the deductible phase.

503A compounding pharmacies licensed in South Dakota may compound alendronate in alternative formulations (such as oral solution for patients with dysphagia or tablet intolerance), but compounding is not appropriate for patients who can tolerate the standard tablet. The FDA's guidance on 503A compounding makes clear that compounding is only permitted when a commercially available product does not meet the individual patient's clinical needs [14].

Prior Authorization Requirements in South Dakota

Most commercial health insurance plans in South Dakota do not require prior authorization (PA) for generic alendronate because it is a low-cost generic. However, some Avera and Sanford health plan formularies and certain employer-sponsored plans may require step therapy, meaning the patient must try and fail a generic bisphosphonate before coverage is granted for a brand-name agent or a non-bisphosphonate such as denosumab (Prolia) or zoledronic acid (Reclast IV).

When prior authorization is required, the documentation typically needed includes:

• DXA report showing T-score -2.5 or below, or T-score between -1.0 and -2.5 with FRAX score meeting BHOF thresholds
• ICD-10 code M81.0 (age-related osteoporosis without pathological fracture) or M80.00 (osteoporosis with current pathological fracture, unspecified site)
• Prescriber attestation that the patient has no contraindications (eGFR <35, esophageal stricture, inability to sit upright)
• Lab results dated within 6 to 12 months confirming calcium, creatinine, and vitamin D status

The AACE/ACE 2020 Clinical Practice Guidelines for Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Alendronate is a first-line therapeutic option for postmenopausal osteoporosis with an extensive safety and efficacy record spanning more than 25 years" [4]. This statement, from a named guideline document, is useful language for PA appeal letters.

PA decisions for generic alendronate are typically returned within 72 hours. If denied, a peer-to-peer review request by the prescribing clinician resolves the majority of denials at the first appeal level. South Dakota law (SDCL 58-17N) requires insurers to respond to urgent PA requests within 72 hours and non-urgent requests within 15 calendar days.

Transferring an Existing Fosamax Prescription to South Dakota

Patients relocating to South Dakota or establishing care with a new SD provider can transfer an existing alendronate prescription under the following conditions.

A pharmacist-to-pharmacist transfer is permitted for non-controlled medications in South Dakota under SDCL 36-11 and the National Association of Boards of Pharmacy (NABP) model rules. The receiving SD pharmacy contacts the originating pharmacy, records the remaining refill authorization, and dispenses from the new location. No new prescription from a South Dakota physician is required for the transfer itself [15].

If the prescription has no remaining refills, a new prescription from a South Dakota-licensed provider is required. A telehealth consultation that includes review of the prior prescription, current DXA, and labs is sufficient to generate a new SD prescription. Most telehealth platforms complete this in a single 15-minute video visit.

Mail-order pharmacies operating across state lines (Express Scripts, CVS Caremark, OptumRx) can continue filling an existing prescription once a patient moves to South Dakota, provided the prescribing clinician is still licensed and the prescription was originally valid. A change-of-address update with the mail-order pharmacy is all that is needed in most cases.

Monitoring Alendronate Therapy in South Dakota

After starting alendronate, follow-up monitoring should occur at predictable intervals to confirm efficacy and catch adverse effects early.

12-month BMD reassessment is not standard for the first repeat DXA. The ISCD 2019 Official Positions recommend a repeat DXA no sooner than 24 months after initiating therapy to assess treatment response, unless clinical suspicion of rapid bone loss exists [8]. A 2019 Cochrane review (13 RCTs, N=7,934) confirmed that BMD gains with alendronate are largely established within the first 12 to 24 months and plateau thereafter [16].

Bone turnover markers (BTMs) such as serum C-telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) can be checked at 3 to 6 months to confirm biochemical response. The International Osteoporosis Foundation recommends a CTX reduction of 25 to 30% from baseline as confirmation of adherence and drug effect [17].

Drug holiday consideration. After 3 to 5 years of alendronate, the American Society for Bone and Mineral Research (ASBMR) task force report recommends reassessing fracture risk to determine whether a 1 to 2 year drug holiday is appropriate for lower-risk patients [18]. Patients with T-score below -2.5 at the femoral neck after 5 years of therapy, or with prior hip or vertebral fracture, should generally continue treatment without a holiday.

Esophageal and GI monitoring. Alendronate must be taken with at least 6 to 8 ounces of plain water, and the patient must remain upright for 30 minutes after ingestion. A 2008 case-control study in the Archives of Internal Medicine reported an odds ratio of 1.30 (95% CI 1.02 to 1.66) for esophageal cancer with 10 or more alendronate prescriptions, though absolute risk remains low and subsequent larger studies have not consistently confirmed this signal [19].

Atypical femur fracture (AFF) surveillance. Patients on long-term bisphosphonate therapy (more than 5 years) should be asked at each visit about new thigh or groin pain. The ASBMR task force estimated the AFF incidence at 3.2 to 50 cases per 100,000 person-years, which is far lower than the hip fractures prevented by therapy [18].

Annual labs. Serum creatinine and calcium should be rechecked annually in patients on alendronate, particularly those over age 70 or with baseline eGFR near the 35 mL/min/1.73 m2 threshold.

Alendronate Versus Other Osteoporosis Treatments Available in South Dakota

Alendronate is not the only bisphosphonate available to South Dakota patients. Comparing it to close alternatives helps clinicians and patients make informed decisions.

Risedronate (Actonel, Atelvia): Also available generically in South Dakota, risedronate 35 mg once weekly has a similar fracture-reduction profile. A 2008 Cochrane review found risedronate reduced vertebral fracture risk by 39% relative to placebo over 3 years [20]. Its upper GI tolerability may be marginally better than alendronate for some patients.

Zoledronic acid (Reclast): A once-yearly 5 mg IV infusion available at Sanford and Avera infusion centers in Sioux Falls and Rapid City. The HORIZON trial (N=7,765) showed a 41% reduction in hip fracture risk at 3 years [21]. Useful for patients with GI intolerance to oral agents or adherence challenges.

Denosumab (Prolia): A subcutaneous injection every 6 months. The FREEDOM trial (N=7,808) reported a 40% reduction in hip fracture risk at 3 years [22]. No renal dose adjustment required, making it an option for patients with eGFR <35 who cannot take alendronate. Available at clinician offices and infusion centers throughout South Dakota.

Raloxifene (Evista): A selective estrogen receptor modulator (SERM) approved for vertebral fracture prevention only. The MORE trial (N=7,705) showed a 30% reduction in vertebral fracture risk at 3 years but no significant reduction in hip fracture risk [23]. Generic available in South Dakota.

For most postmenopausal South Dakota women with a new diagnosis of osteoporosis and no contraindications, generic alendronate 70 mg once weekly remains the cost-effective first choice per AACE and BHOF guidelines [4][5].